, Tracking Stock Market Picks
Enter Symbol:
Repros Therapeutics Inc. (RPRX) [hlAlert]


Repros Therapeutics Inc. (RPRX) downgraded to Hold with price target $4 by Roth Capital

Posted on: Thursday,  Jul 23, 2009  8:55 PM ET by Roth Capital

Roth Capital rated Hold Repros Therapeutics Inc. (NASDAQ: RPRX) on 07/23/2009. Previously Roth Capital rated Buy Repros
Therapeutics Inc. (NASDAQ: RPRX) on 12/05/2008., when the stock price was $8.90. Since then, Repros Therapeutics Inc. has lost 69.33% of its value until Roth Capital rated RPRX Buy on 07/23/2009, when the price was $2.73. .

Repros Therapeutics Inc. (RPRX) is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs. The Company's principal drug, Proellex, is a selective blocker of the progesterone receptor and is being developed for the treatment of uterine fibroids, anemia associated with excessive menstrual bleeding relating to uterine fibroids, or anemia associated with uterine fibroids and endometriosis. The second product candidate, Androxal, is a single isomer of clomiphene citrate and an orally active small molecule compound.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/21/2012 8:25 AM Buy
as of 12/31/2009
1 Week   
1 Month   
3 Months   
1 YTD down  -74.04 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/23/2009 8:55 PM Hold
2.73 4.00
12/5/2008 8:25 AM Buy
8.90 19.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy